Use of elagolix for the management of endometriosis-associated pain: secondary efficacy results from two randomized, placebo-controlled studies
article
OA: bronze
CC0
⤵ 4 in-corpus citations
AI-generated summary
Elagolix significantly reduced endometriosis-associated pain in women by suppressing estradiol levels, as demonstrated in two randomized, placebo-controlled studies.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (4)
- Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment 2019
- Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature 2017
- The unbearable burden of endometriosis: Results from a large cohort about anxiety reduction during the first outpatient evaluation 2021
- Endometriosis – a decade later – still an enigmatic disease. What is the new in the diagnosis and treatment? 2019
Cited by (4)
- The unbearable burden of endometriosis: Results from a large cohort about anxiety reduction during the first outpatient evaluation 2021
- Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment 2019
- Endometriosis – a decade later – still an enigmatic disease. What is the new in the diagnosis and treatment? 2019
- Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature 2017
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK